Tristan Ferry
University of Lyon, France
Tristan Ferry graduated from the Claude Bernard Lyon 1 University, Lyon, France and he is currently the co-head of the Infectious and Tropical disease unit in Hospices Civils de Lyon. He is head of the Lyon referral center for the management of complex bone and joint infections (CRIOAc Lyon), and of the Lyon Bone and Joint Infection (BJI) group (a multidisciplinary group with colleagues specialized in infectious disease, surgery, microbiology, imaging, nuclear medicine and drug’s pharmacokinetic). His main topic of research is the promotion of innovative treatments, by systemic and/or local administrations in patients with bone and joint infection, and also in patients suffering from other severe bacterial infections such as complex lung infections and endocarditis. He is particularly involved in the promotion and evaluation of phage therapy and the use of phage lysins in patients with BJI. He is a pioneer as physician in lysin treatment in humans: he treated his first patient in 2019, set up a dedicated approach (LysinDAIR) to treat patients with complex prosthetic joint infections, and was the clinical coordinator of the first clinical trial that has been launched in the field. He is one of the inauguration committee members of the new ESCMID Study Group for Non-Traditional Antibacterial therapy (ESGNTA) and has been elected in April 2022 as member of the executive committee as Clinical Officer. He is also member of the board of the European Bone and Joint Infection Society (EBJIS). He would like to facilitate the developement of phage therapy centers, but also would like to facilitate the performance of multicentric clinical trials in Europe throughout the ESGNTA and EBJIS networks, to evaluate academic and industrial new treatment options such as bacteriophages and lysins. Check his profile and his posts on LinkedIn.
Affiliations: (1). Hospices Civils de Lyon (2). Université Claude Bernard Lyon (3). Centre de reference des Infections Ostéoarticulaires complexes CRIOAc Lyon
Prosthetic joint infection (PJI) is the most dramatic complication after joint arthroplasty. S. aureus and coagulase-negative staphylococci are frequently involved in patients with PJI. These bacteria could be involved in recurrence as they can produce biofilm and persist at the implant surface. Phage therapy has been developed for patients infected with S. aureus, but it seems to be more difficult to develop phage therapy to target coagulase-negative staphylococci. In patients with biofilm-associated coagulase-negative staphylococci PJI, the standard of care is to explant/exchange the infected prosthesis, a complex surgical procedure at risk of complication and that could be associated with bone loss, loss of function and potentially with amputation in case of iterative failures. Lysin CF-301 (also called exebacase) is an anti-staphylococcal lysin with potent bactericidal activity against coagulase-negative staphylococci and shown to disrupt mature biofilms formed by these bacteria. In 2019, we set-up at the referral centers for the management of complex Bone and Joint Infections called “CRIOAc Lyon”, a conservative approach for patient experiencing coagulase-negative staphylococci PJI called LysinDAIR, that is the intraarticular administration of CF-301 during arthroscopy, a mini-invasive surgical technic. We treated the first case as compassionate use in 2019, and a clinical trial was started but then stopped, due to the bankruptcy of the company that developed CF-301 in December 2023. In the work presented here, we report this unique experience of first consecutive applications of a phage-derivated lysin in humans, with feedback about its safety and efficacy during a long-term follow-up.